| scholarly article | Q13442814 |
| P50 | author | Yu Huang | Q56528909 |
| Wing Tak Wong | Q56988879 | ||
| Xiaoqiang Yao | Q57009857 | ||
| Vivian Wing Yan Lee | Q81457412 | ||
| P2093 | author name string | Y Lu | |
| Z Y Chen | |||
| A Xu | |||
| L M Liu | |||
| X Y Tian | |||
| C W Lau | |||
| P2860 | cites work | Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. | Q51801075 |
| HMG-CoA Reductase Inhibitors Decrease Angiotensin II–Induced Vascular Fibrosis | Q61854913 | ||
| Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men | Q73205391 | ||
| Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus | Q79706677 | ||
| Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice | Q79948551 | ||
| Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice | Q80477528 | ||
| The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation | Q80580061 | ||
| Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering | Q31807283 | ||
| Endothelial dysfunction in diabetes. | Q33959485 | ||
| Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. | Q34149216 | ||
| Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2. | Q34742771 | ||
| Role of C-reactive protein in the assessment of cardiovascular risk | Q35042927 | ||
| The roles of hyperglycaemia and oxidative stress in the rise and collapse of the natural protective mechanism against vascular endothelial cell dysfunction in diabetes | Q37044976 | ||
| Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment | Q37196829 | ||
| Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. | Q37245109 | ||
| Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling | Q37380419 | ||
| Endothelial dysfunction: the common consequence in diabetes and hypertension. | Q37737686 | ||
| Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. | Q39878461 | ||
| Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice | Q43171566 | ||
| HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species | Q43641701 | ||
| Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts | Q43735838 | ||
| Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering | Q44564063 | ||
| Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial | Q44599698 | ||
| Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker | Q44614425 | ||
| Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy | Q45012594 | ||
| Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. | Q45037051 | ||
| Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice | Q45234516 | ||
| Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels | Q45280966 | ||
| Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. | Q45954983 | ||
| Effects of statins on vascular endothelial function in hypercholesterolemic patients with type 2 diabetes mellitus: fluvastatin vs. rosuvastatin | Q46143681 | ||
| Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors | Q46211676 | ||
| Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade | Q46443790 | ||
| Participation of K+ channels in the endothelium-dependent and endothelium-independent components of the relaxant effect of rosuvastatin in rat aortic rings | Q46477436 | ||
| Effect of rosuvastatin on capillary filtration of albumin and blood pressure in rats with streptozotocin-induced diabetes | Q46649543 | ||
| Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). | Q46730270 | ||
| Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production | Q46801152 | ||
| The protective effect of rosuvastatin in human umbilical endothelial cells exposed to constant or intermittent high glucose | Q46811479 | ||
| Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. | Q46862910 | ||
| Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. | Q46879881 | ||
| Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. | Q51559365 | ||
| Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga | Q51566349 | ||
| P433 | issue | 2b | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 598-606 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress | |
| P478 | volume | 164 |
| Q36996652 | Activation of renin-angiotensin system is involved in dyslipidemia-mediated renal injuries in apolipoprotein E knockout mice and HK-2 cells |
| Q46843512 | Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial |
| Q36994190 | Astaxanthin attenuates the apoptosis of retinal ganglion cells in db/db mice by inhibition of oxidative stress |
| Q38208727 | Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. |
| Q26991619 | Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system |
| Q35705401 | Boldine Ameliorates Vascular Oxidative Stress and Endothelial Dysfunction: Therapeutic Implication for Hypertension and Diabetes |
| Q41824130 | Boldine improves endothelial function in diabetic db/db mice through inhibition of angiotensin II-mediated BMP4-oxidative stress cascade |
| Q55405814 | Comparison of Pulmonary and Systemic NO- and PGI2-Dependent Endothelial Function in Diabetic Mice. |
| Q41652967 | Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis |
| Q54989042 | Effect of rosuvastatin on the expression of candidate gene GALNT3 in atherosclerosis. |
| Q37707720 | Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells. |
| Q51317623 | PTEN upregulation may explain the development of insulin resistance and type 2 diabetes with high dose statins. |
| Q85427908 | Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities |
| Q47377607 | Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering |
| Q47835623 | Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells |
| Q90605122 | Rosuvastatin reverses hypertension-induced changes in the aorta structure and endothelium-dependent relaxation in rats through suppression of apoptosis and inflammation |
| Q47903414 | Saxagliptin prevents vascular remodeling and oxidative stress in db/db mice. Role of endothelial nitric oxide synthase uncoupling and cyclooxygenase |
| Q36672866 | The endothelium in diabetes: its role in insulin access and diabetic complications |
| Q28076034 | Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola |
| Q46819734 | Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways |
Search more.